Kornimate/medical-research-clean huggingface dataset:
pain neuroscience education, motor imagery and action observation in patients with chronic temporomandibular disorders.

Conditions: TMD

Summary: the objective of this study will be to verify the additional effect of pain neuroscience education, motor imagery and action observation on primary outcomes pain intensity and craniofacial pain and disability in patients with chronic temporomandibular disorders (tmd). the secondary outcomes will be pressure pain threshold, temporal summation, conditioned pain modulation, central sensibilization, pain catastrophizing, kinesiophobia. this study will be a doble-blinded randomized clinical trial comprising a sample of 50 participants with orofacial pain of both genders and aged between 18 and 60 years. subjects will undergo a screening process to identify those presenting a diagnosis of painful tmd confirmed by the diagnostic criteria for temporomandibular disorders (dc/tmd), and then they will be randomized into two groups (g1: occlusal splint, counselling and jaw and neck exercises vs. (g2: occlusal splint, jaw and neck exercises plus pain neuroscience education, motor imagery and action observation). these volunteers will be recruited from the alisos group dentistry clinic and university of gran rosario, (rosario, argentina). all patients will wear an occlusal splint designed by dentists. the interventions will be administered twice a week for 5 weeks by a single therapist. subsequently, patients will be given instructions to perform the exercises at home for 5 weeks. primary and secondary outcomes will be measured at baseline, 6 weeks and 12 weeks, and at 3 months after the end of treatment (follow-up). all the evaluations will be performed by a blinded physiotherapist.


Eligibility criteria:
inclusion criteria: * a diagnosis of painful tmd using the diagnostic criteria for temporomandibular disorders (dc/tmd) * a history of orofacial pain during at least three months prior to the study * age ranging between 18 to 65 years, both genders. exclusion criteria: • patients with neurological disorders (neuropathic pain or neurodegenerative disease), whiplash associated disorders, specific neck pain (radicular pain), recent dental or physical therapy. if patients are taking medication to relieve pain during the study, they will be encouraged to report it.

Keywords: pain neuroscience education motor imagery action observation exercises occlusal splint
combined therapy in age-related macular degeneration (armd)

Conditions: Age-Related Macular Degeneration

Summary: the purpose of this study is to investigate the efficacy of combined intravitreal therapy with or without prior photodynamic therapy in patients with wet age-related macular degeneration (amd). in patients with wet amd, a significant improvement in vision was observed after combined intravitreal therapy with or without prior photodynamic therapy. both the pharmacological effects of the drugs and the physiological effects of the pars plana vitrectomy (posterior vitreous detachment, liquefaction, and oxygen redistribution) may have contributed to the long-term sustainability of the therapeutic benefits.

this prospective study of a case series included eyes with predominantly classic lesions (group 1; n = 52) and eyes with occult lesions (group 2; n = 106). patients with predominantly classic lesions received low fluorescence photodynamic therapy (42 j/cm2 for 72 sec), followed by, 24 hours later, a 1.5 ml core pars plana vitrectomy with intravitreal injection of dexamethasone (0.8 mg) and bevacizumab (1.25 mg). patients with occult lesions received a 0.4 ml core pars plana vitrectomy with intravitreal injection of triamcinolone (8 mg) and bevacizumab (1.25 mg). at baseline and follow-up examinations, the best-corrected visual acuity (bcva; logmar), central macular thickness (optical coherence tomography), intraocular pressure (iop; goldmann tonometry) were determined. in addition, the need for retreatment was assessed, and adverse events were monitored.

Eligibility criteria:
inclusion criteria: * wet age related macular degeneration exclusion criteria: * opacities in lens or cornea * ongoing intraocular inflammation * trauma

Keywords: armd combined therapy efficacy safety
double-blind, placebo-controlled study to evaluate 3 doses of a novel tetracycline in the treatment of facial acne vulgaris

Conditions: Acne Vulgaris

Summary: to evaluate the safety and effectiveness of 3 strengths of p005672-hcl compared to placebo for the treatment of moderate to severe facial acne vulgaris.


Eligibility criteria:
inclusion criteria: * if women of child-bearing potential, have a negative urine pregnancy test * willing to use only a non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study * male or female, 12-45 years of age with body weight between 52 and 88 kg * diagnosis of acne vulgaris with: 20 to 50 inflammatory lesions (papules, pustules, and nodules) 30 to 100 noninflammatory lesions (open and closed comedones) * no more than 2 nodules on the face * investigator's global assessment (iga) score of moderate (3) to severe (4) exclusion criteria: * dermatological condition of face or facial hair that could interfere with clinical evaluations subjects who have used the following medications (topical refers only to the facial area) will not be eligible: within 1 week prior to randomization: * medicated facial cleansers * topical acne treatments (other than those listed below) within 4 weeks prior to randomization: * topical retinoids * topical anti-inflammatories and corticosteroids * systemic antibiotics * systemic acne treatments within 12 weeks prior to randomization: * systemic retinoids * systemic corticosteroids * pseudomembranous colitis or antibiotic-associated colitis * hepatitis, liver damage or renal impairment

Keywords: acne
intraventricular catheter system for ivh

Conditions: Intraventricular Hemorrhage (IVH)

Summary: the purpose of this research study is to evaluate the safety and outcomes associated with the use of irraflow® system catheters in externally draining intracranial fluid to reduce intracranial pressure. this study will be comparing the irraflow® system to standard of care catheters used in the same procedure. the irraflow® system is fda approved for this procedure.

intracranial hemorrhagic conditions can rapidly cause brain damage and often considered life- threatening. of these, intracerebral hemorrhagic (ich) is the most common type of hemorrhagic stroke and is associated with higher rates of morbidity and mortality than all stroke subtypes. management of hemorrhagic patients is typically orchestrated by neurosurgeons and neuro-intensivists. comprehensive care should include surveillance and monitoring of intra cranial pressure (icp), cerebral perfusion pressure (cpp), and hemodynamic function. furthermore, prevention of infection, complications of immobility through positioning and mobilization within physiological tolerance play an important role in optimizing outcomes after ich. there are multiple approaches to facilitating cerebrospinal fluid (csf) drainage and monitor icp. routinely, intracranial pressure is measured by use of devices inserted into the brain parenchyma or cerebral ventricles. a ventricular catheter (vc) inserted into the lateral ventricle allows for drainage of csf to help reduce icp. although csf drainage is a vital sequence in patient management, there are reported risks including infection and limitations related to erroneous readings associated with current icp monitors. physicians lack the appropriate tools to employ active intermittent aspiration and drainage with continuous icp monitoring. the current clinical study is being initiated to evaluate the hypothesis that active irrigation by irraflow will reduce the time needed for clearance of intraventricular blood from intraventricular space.

Eligibility criteria:
inclusion criteria: * age \>=18 years of age * intraventricular hemorrhage documented on head ct or mri scan * need of cerebrospinal fluid drainage * indication for active treatment evaluated by the treating physicians * signed informed consent obtained by patient or legal authorized representative * treatment possible within 72 hours of ictus exclusion criteria: * patient has fixed and dilated pupils * pregnant or nursing women (fertile female participants will be required to take a validated pregnancy test for evaluation of pregnancy)
alemtuzumab (campath 1h) associated to g-csf in adult patients with refractory acute lymphocytic leukemia

Conditions: Acute Lymphocytic Leukemia

Summary: alemtuzumab is an anti cd52 monoclonal antibody. the cd52 antigen is present at the surface of b,t nk lymphocytes. it is expressed at various levels at the surface of all blast cells. adult patients with all in relapse have less than 10% probability of long term survival. the present study will test the response rate (partial and complete remission) of refractory all or all in relapse. it is hoped that if a cr can be achieved, further consideration will be given for a hematopoietic stem cell transplant. the use of g-csf is justified by a possible increase in adcc.

all patients receive alemtuzumab in 3 successive phases: phase a: test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance. phase b: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented. phase c: in patients in cr, maintenance with alemtuzumab: 3 injections one week every 2 months.

Eligibility criteria:
inclusion criteria: * patients older than 15 years * refractory all * all in relapse post chemotherapy or post transplant * all blast cells expressing cd 52 antigen at any time during the evolution of the disease. * signed informed consent * patients under social security coverage * anti conceptional tablets in pre menopausal women. exclusion criteria: * children below 15 years of age or aged 15 * blast cells not expressing cd52 antigen (at all evaluations) * hiv positivity * ecog score 3 and 4 * hypersensitivity to alemtuzumab. * pregnancy or breast feeding. * other malignant disease in addition to all.

Keywords: adult acute lymphocytic leukemia alemtuzumab
comparative study on surgical approaches for elderly femoral neck fractures

Conditions: Function; Pain

Summary: a prospective controlled study was conducted to include patients who received hip replacement surgery for femoral neck fractures at the national regional trauma center in fujian province from february 2023 to august 2024. patients were randomly divided into the daa group and the pla group based on different surgical methods for a 3-month follow-up to compare the outcomes of the two groups. the main observation results include harris hip joint function score (preoperative, postoperative 1 week, 1 month, 3 months), vas pain score (preoperative, postoperative 1 week, 1 month, 3 months), and secondary observation results include surgical time, intraoperative blood loss, blood transfusion rate, difference in hb before and after surgery, difference in ck before and after surgery, perioperative complications, difference in length of both lower limbs after surgery, postoperative drainage volume, postoperative icu occupancy rate, icu length of stay, and total length of stay.


Eligibility criteria:
inclusion criteria: 1. age ≥ 80 years old; 2. diagnosed with unilateral femoral neck fracture through imaging examination; 3. patients who can tolerate surgery and agree to undergo surgery; 4. undergoing hemiarthroplasty (ha) for the first time; 5. able to walk independently and have intact cognitive function before the injury. exclusion criteria: 1. bilateral femoral neck fractures; 2. patients with pathological fractures; 3. hip dysplasia, rheumatoid osteoarthritis, or other hip disorders; 4. patients with systemic or localized infections or inflammatory reactions at the surgical site; 5. patients with other lower limb fractures or severe injuries to other parts of the body; patients with a history of previous hip surgery.

Keywords: femoral neck fractures direct anterior approach hemiarthroplasty
probiotic bladder instillation for prevention of catheter associated utis in chronically catheterized patients

Conditions: Urinary Tract Infections

Summary: the proposed study is a randomized, placebo-controlled clinical trial to test the efficacy of an oral lactobacillus product dissolved in sterile saline and instilled into the urinary bladder in an attempt to colonize the urinary bladder as well as prevent utis.

patients who use a chronic indwelling urinary catheter to drain their bladder will be randomized to receive intravesical instillations of a lactobacillus solution or sterile saline at the time of a scheduled monthly catheter exchange. bacterial colonization and frequency of urinary tract infections will be compared between the two groups. the lactobacillus solution will be derived from the combination of lactobacillus rhamnosus (gr-1®) and reuteri (rc-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of femdophilus and manufactured by chr-hansen of denmark (phone: +45 45747474; email: info@chr-hansen.com). the contents of the capsules will be dissolved in 50 ml of normal saline at room temperature within one hour prior to administration and left indwelling in the patient's urinary bladder for 30 minutes.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. chronic indwelling urethral catheter or supra-pubic tube for \>6 months 3. prior symptomatic uti while catheter in place exclusion criteria: 1. immunosuppressed (hiv, transplant immunosuppression, uncontrolled diabetes) 2. active infection (may be considered after treatment of active infection) 3. prior urosepsis requiring icu admission 4. significant gross hematuria resulting from catheter exchanges 5. supravesical urinary diversion 6. upper urinary tract anatomical abnormality 7. obstructing urolithiasis 8. ongoing antibiotic therapy for non-urological infection 9. indwelling nephrostomy tube or ureteral stent 10. radiation cystitis 11. pregnancy
clavulanic acid for the treatment of cocaine use disorder

Conditions: Cocaine Dependence

Summary: a dose escalation study to assess the efficacy and safety of clavulanic acid (clav) vs. placebo (pbo) for the treatment of cocaine use disorder (cud)

this pilot study is indicated for treatment of moderate to severe cocaine use disorder. it is a randomized, placebo-controlled, parallel group, multi-center pilot study to compare the efficacy of 500-750mg/day clavulanic acid vs. placebo in addition to weekly medication management therapy. subjective, cognitive, and adverse effect assessments, blood pressure and pulse will be performed 1-3 times weekly.

Eligibility criteria:
inclusion criteria: * be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures * be male or female adult volunteers ages 18-70 inclusive. * have a diagnostic and statistical manual (dsm-v) diagnosis of cocaine use disorder, moderate to severe in early remission with a duration of regular (weekly or more) cocaine (either snorted, smoked or injected) for at least one year. * have a history and brief physical examination that demonstrate no clinically significant contraindication for participating in the study, and/ or significant or unstable medical or psychiatric illness. exclusion criteria: * meets dsm-v criteria for dependence on any substance other than cocaine and mild to moderate alcohol or marijuana (except nicotine or caffeine), determined by the structured clinical interview for dsm-v. * allergy to clavulanic acid, penicillin, or any beta-lactam drug. * meets current or lifetime dsm-v criteria for schizophrenia or any psychotic disorder or organic mental disorder. subject meets current dsm-v diagnosis of any other clinically significant psychiatric disorder that will interfere with study participation. * severe physical or medical illnesses such as aids or active hepatitis. * if female, tests positive on a pregnancy test, is contemplating pregnancy in the next 6 months, is nursing, or is not using an effective contraceptive method (if relevant)
obesity and jobs in socioeconomically disadvantaged communities: a randomized clinical precision public health intervention --the sculpt-job study

Conditions: Weight Maintenance; Weight Loss; Stress, Psychological; Job Stress; Diabetes Prevention; Obesity; Cardiovascular Risk Factor; Cardiovascular Diseases

Summary: this is an interventional research study about clinical, psychosocial, and behavioral factors that impact weight loss, weight maintenance, and cardiovascular disease in socially disadvantaged persons.

the purpose of this study is to understand whether the incorporation of social determinants of health into a weight loss/maintenance study, along with a known behavioral intervention will result in improved efficacy than the behavioral intervention by itself. this study will examine the role of psychosocial, clinical, and behavioral factors in the context of the intervention. the entire duration of the study will be 18 months. study activities will occur virtually or at ymca locations in the city of san francisco or at other community centers.

Eligibility criteria:
inclusion criteria: * participants from disadvantaged backgrounds (average median household approximately $31,000 household income/ 4 people, * participants in the federal medicaid insurance program or medical, * age \> 18 years old, * and bmi \> 25 kg/m2 (for asian ethnicity bmi\> 22 kg/m2). exclusion criteria: * pregnancy or post-partum state (\< 12 months post-partum), * history of diabetes (type 1 or 2), * history of myocardial infarction, stroke or cardiac arrest in the prior 2 years, * history of physician diagnosed cognitive, developmental or psychiatric conditions, recent orthopedic diagnosis or surgery (\< 6 months), * and persons facing housing eviction or undergoing an active housing leasing process (e.g getting their credit report in shape for a potential lease, in the process of getting a new housing lease).
electrosurgical bipolar plasmakinetic vessel sealing during abdominal hysterectomy: a randomized controlled trial

Conditions: Abdominal Hysterectomy for Benign Disease

Summary: objective: to compare the safety and efficacy of the use of bipolar plasmakinetic vessel sealing (gyrus pk) usage versus standard technique when performing total abdominal hysterectomy for benign disease. material and methods: controlled randomized trial involving 94 women who underwent total abdominal hysterectomy. 47 procedures were performed using bipolar plasmakinetic vessel sealing and the remaining 47 with the standard sutures technique. the primary outcomes were improvement in terms of blood loss, procedure time, length of hospital stay, and overall cost of the procedure. statistical methodology considered significant p \<0.05.

all patients were right-holders of the petroleos mexicanos (mexican oil company) medical network who required hysterectomy surgical treatment for benign causes all patients included in the study signed an informed consent form, knowing all possible implications of the procedure patients were randomly assigned to one of the two techniques: 1. plasmakinetic bipolar energy forceps (gyrus pk) and 2. standard technique using sutures the surgical steps other than placement of suture are identical to those used during standard abdominal hysterectomy. time of the procedure was considered from the moment skin was first cut-open, until it was fully closed, previously checking satisfactory homeostasis. blood loss was estimated by the anesthesiology service. further data compiled included time spent in hospital and the total cost of the procedure. post-surgery complications were recorded at the follow up visits one and 4 weeks after the surgery.

Eligibility criteria:
inclusion criteria: * any patient with a benign disease as indication for hysterectomy exclusion criteria: * hysterectomy for malignant pathology * laparoscopic or vaginal hysterectomy * any patient in which the procedure used both techniques * obstetric hysterectomy

Keywords: electrosurgery gyrus pk abdominal hysterectomy blood loss, surgical length of stay overall cost
trial of gemcitabine, cisplatin, and ifosfamide in patients with relapsed non-seminomatous germ-cell tumors

Conditions: Germ Cell Tumor

Summary: this is a prospective multicenter phase ii trial of gemcitabine, cisplatin, and ifosfamide (gip) in patients with relapsed non-seminomatous germ-cell tumors (nsgct) and a predicted favorable prognosis.


Eligibility criteria:
inclusion criteria: * patients older than 16 years * histologically-proven disseminated (non stage i) nsgct, or diagnosis of nsgct based on very elevated serum human chorionic gonadotropin (hcg) and/or alpha fetoprotein (afp) * relapsed disease classified as good prognosis according to the memorial sloan-kettering cancer center (mskcc) classification criteria: * testicular primary site * prior treatment limited to one program (or 6 or fewer cycles of cisplatin) * either a complete response or a partial response with normal serum afp and hcg * relapse documented by rising afp and/or hcg or by a biopsy * no previous carcinoma, except basal-cell carcinoma of the skin * adequate renal function: measured or calculated creatinine clearance\> 60 ml/min * absolute granulocyte count \>= 1,500/mm3, platelets \>= 100,000 mm3, bilirubin \< 1.5 fold the upper normal value * signed informed consent. exclusion criteria: * patients infected by the human immunodeficiency virus (hiv) * patients who do not fit inclusion criteria

Keywords: patients with relapsed non-seminomatous germ-cell tumors (nsgct)
improve osteoarthritis care

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the purpose of the improve osteoarthritis care study is to improve the quality of osteoarthritis care in norwegian primary care, by increasing the use of recommended treatment modalities and improving patient access to recommended treatments. the study will use tailored implementation strategies, targeting primary care physicians and physiotherapists to improve knowledge and addressing individual barriers to providing recommended treatments.

previous research has shown that current osteoarthritis care for persons with hip or knee osteoarthritis (oa) in norway has a potential for improvement as the provided care may not necessarily reflect evidence-based guideline recommendations. the overall purpose of the "improve osteoarthritis care" study is that people with symptomatic hip and knee oa should receive care in line with current recommendations. to achieve this goal, tailored implementation strategies will be applied in order to: 1) improve the quality of care offered to people with symptomatic hip and knee oa, 2) increase knowledge of recommended oa care among people with hip and knee oa, 3) increase the number of primary care physiotherapists' offering group-based patient-education and structured exercise as part of their routine clinical practice, 4) increase the number of general practitioners who have received a summary of the oa treatment recommendations. to evaluate the effect of the tailored implementation strategy a pre-post design will be applied, and members of the norwegian rheumatology association with self-reported hip or knee oa will be asked to evaluate quality of oa care at the two timepoints.

Eligibility criteria:
inclusion criteria: * self-reported hip or knee osteoarthritis exclusion criteria: * persons who do not understand the norwegian language

Keywords: implementation treatment guidelines